2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169221
    Perindopril arginine 612548-45-5 99.32%
    Perindopril arginine is an angiotensin-converting enzyme inhibitor with hypotensive activity. Perindopril arginine is used to inhibit hypertension to lower blood pressure. Perindopril arginine, when used in combination with indapamide and amlodipine, can effectively lower blood pressure and provide better target organ protection.
    Perindopril arginine
  • HY-169472
    11-Deoxy prostaglandin F1β 37785-99-2 98%
    11-Deoxy prostaglandin F1β is a synthetic analog of PGF1β. 11-Deoxy prostaglandin F1β exhibits vasodepressor and bronchodilator activities in guinea pigs.
    11-Deoxy prostaglandin F1β
  • HY-169555
    ASK1-IN-7 1427537-92-5 98%
    ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. ASK1-IN-7 holds promise for research related to the ASK1 signaling pathway, such as cell stress responses, inflammation, neurodegenerative diseases, and cardiovascular diseases.
    ASK1-IN-7
  • HY-169626
    VEGFR-IN-6 683235-34-9 98%
    VEGFR-IN-6 (Compound 3) is a vascular endothelial growth factor receptor (VEGFR) inhibitor. VEGFR-IN-6 can inhibit angiogenesis. VEGFR-IN-6 is promising for research of tumor diseases that rely on angiogenesis.
    VEGFR-IN-6
  • HY-169627
    VEGFR-IN-7 683235-33-8 98%
    VEGFR-IN-7 (Compound 2) is a VEGFR inhibitor, showing inhibition of angiogenesis to a lesser extent. VEGFR-IN-7 is promising for research of cardiovascular diseases.
    VEGFR-IN-7
  • HY-169752
    APJ receptor agonist 11 2135515-67-0 98%
    APJ receptor agonist 11 (Ex 174) is a APJ receptor agonist with IC50 values ranging from 0.01 nM to 10 nM. APJ receptor agonist 11 can be used in the study of cardiovascular diseases.
    APJ receptor agonist 11
  • HY-169788
    Graveolinine 4179-37-7 98%
    Graveolinine is a quinoline alkaloid, that can be isolated from Ruta chalepensis. Graveolinine exhibits antiplatelet activity, that reduces Arachidonic Acid (HY-109590)- and Collagen-induced aggregation of washed rabbit platelets.
    Graveolinine
  • HY-169836
    Des-ethyl-carafiban 170565-45-4 98%
    Des-ethyl-carafiban (Compound 44) is a fibrinogen receptor antagonist that can effectively inhibit platelet aggregation induced by multiple agonists. Des-ethyl-carafiban can be used in the research of thrombotic diseases.
    Des-ethyl-carafiban
  • HY-16991R
    Terutroban (Standard) 165538-40-9 98%
    Terutroban (Standard) is the analytical standard of Terutroban. This product is intended for research and analytical applications. Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties.
    Terutroban (Standard)
  • HY-17000R
    Tolvaptan (Standard) 150683-30-0 98%
    Tolvaptan (Standard) is the analytical standard of Tolvaptan. This product is intended for research and analytical applications. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia.
    Tolvaptan (Standard)
  • HY-17000S
    Tolvaptan-d7 1246818-18-7 98%
    Tolvaptan-d7 is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation.
    Tolvaptan-d7
  • HY-17004R
    Olmesartan (Standard) 144689-24-7 98%
    Olmesartan (Standard) is the analytical standard of Olmesartan. This product is intended for research and analytical applications. Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.
    Olmesartan (Standard)
  • HY-17007R
    Saquinavir (Standard) 127779-20-8 98%
    Saquinavir (Standard) (Ro 31-8959 (Standard)) is the analytical standard of Saquinavir (HY-17007). This product is intended for research and analytical applications. Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir (Standard)
  • HY-171248
    CDD-1115 3034215-86-3 98%
    CDD-1115 is a potent, selective inhibitor of BMPR2 with IC50 of 1.8 nM, Kiapp of 6.2 nM. CDD-1115 inhibits bone morphogenetic protein (BMP)-mediated gene expression. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation.
    CDD-1115
  • HY-171449
    SCH 211803 331765-50-5 98%
    SCH 211803 is a selective antagonist of the M2 muscarinic receptor. SCH 211803 is promising for research of cardiovascular and nervous system diseases.
    SCH 211803
  • HY-171464
    Lp(a)-IN-5 2924841-79-0 98%
    Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC50 value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.
    Lp(a)-IN-5
  • HY-171469
    SKP-451 181137-41-7 98%
    SKP-451 is an ATP-sensitive potassium (K+) channel agonist. SKP-451 activates the ATP-sensitive K+ channels, promotes the efflux of K+, causes membrane hyperpolarization, and inhibits the influx of Ca2+, thereby relaxing the vascular smooth muscle. SKP-451 relaxs the canine coronary artery, rabbit basilar artery, and vertebral artery. SKP-451 also reduces the mean arterial blood pressure of conscious spontaneously hypertensive rats (SHR). SKP-451 is promising for research of cardiovascular diseases.
    SKP-451
  • HY-172228
    RPR-101511 146535-06-0 98%
    RPR-101511 is a 3-substituted quinoline derivative. RPR-101511 is a PDGF receptor tyrosine kinase inhibitor (IC50: 0.001-0.02 μM).
    RPR-101511
  • HY-172297
    Pyrazole N-Desmethyl sildenafil 139755-95-6 98%
    Pyrazole N-Desmethyl sildenafil (Compound 10) is an analog of Sildenafil (HY-15025). Pyrazole N-Desmethyl sildenafil shows 16% inhibition on Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) with 100 µM.
    Pyrazole N-Desmethyl sildenafil
  • HY-17352A
    Clazosentan disodium 503271-02-1 99.94%
    Clazosentan disodium (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan disodium inhibits ET-1-mediated vasoconstriction. Clazosentan disodium prevents cerebral vasospasm, vasospasm-related cerebral infarction.
    Clazosentan disodium
Cat. No. Product Name / Synonyms Application Reactivity